Background There is no standard second-line treatment for patients with platinum refractory advanced B3-Thymoma (T) and thymic carcinoma (TC). In this population, the PECATI trial testing lenvatinib plus pembrolizumab met its primary endpoint, with 5-month progression-free survival (PFS) of 88.0% (90% CI: 73.5–94.8). M...
Jordi Remon, Paolo Bironzo, Nicolas Girard et al.· Mediastinum· 0 citations
Immune checkpoint blockade (ICB) has reshaped the treatment of advanced non-small cell lung cancer (NSCLC), yet durable benefit remains limited to a subset of patients. One major pattern of resistance is immune exclusion, in which CD8+ T cells accumulate in stromal regions but fail to penetrate tumor nests. Here, using...
J. Guégan, Benjamin Bonhomme, F. Peyraud et al.· Signal Transduction and Targ...· 0 citations
BACKGROUND
Pembrolizumab, alone or combined with platinum-based chemotherapy, is a standard first-line treatment for patients with metastatic non-small-cell lung cancer (NSCLC) without actionable oncogenic alterations and with high programmed death-ligand 1 (PD-L1) expression. We conducted a head-to-head comparison of...
R. Descourt, A. Mogenet, Maelys Consigny et al.· Annals of Oncology· 0 citations
INTRODUCTION
Identification of populations eligible for lung cancer screening (LCS) is a priority question in this field. The primary objective of this study was to quantify lung cancer prevalence after a first round of LCS among patients with history of atheromatous cardiovascular disease (aCVD) and tobacco exposure....
Elsa Armand, C. Buton, Caroline Caramella et al.· Respiratory medical research· 0 citations
Final analyses from this phase 2 study further supported substantial activity and prolonged OS with lorlatinib in treatment-naive and previously treated patients with ALK-positive advanced NSCLC, regardless of the biomarker subgroups.
T. Bauer, J. Martini, B. Besse et al.· Journal of Thoracic Oncology· 0 citations
RAS alterations mediate resistance to targeted agents in approximately 10% of oncogene-driven lung cancer, and Rational combinations with novel RAS inhibitors are effective in preclinical models, providing the basis for their clinical investigation and extending the paradigm of precision oncology.
F. Facchinetti, L. Friboulet, L. Liao et al.· Annals of Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.